Could a simple pill stop lungs from scarring? new trial launches

NCT ID NCT06714123

Recruiting now Disease control Sponsor: Vejle Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug senicapoc can prevent lung scarring from getting worse in people with progressive fibrotic interstitial lung disease (ILD) or idiopathic pulmonary fibrosis (IPF). About 140 adults will take either senicapoc or a placebo daily for 26 weeks, and doctors will track lung function, side effects, and quality of life. The goal is to see if senicapoc can slow the decline in breathing capacity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Senicapoc (a drug taken as tablets)
What this could lead to: If it works, this could point toward a new treatment to slow lung scarring and preserve breathing function in people with fibrotic lung disease.
What could go wrong: This is an early Phase 2 trial with only 140 participants, so results may not confirm benefit. The drug may cause side effects or fail to outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis interstitial lung disease pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS PULMONARY FIBROSIS, INTERSTITIAL LUNG DISEASE

Contacts and locations

Locations

Aarhus University Hospital
RECRUITING

Aarhus N, 8200, Denmark
Division of Respiratory Sciences, Glenfield Hospital
NOT_YET_RECRUITING

Leicester, LE3 9QP, United Kingdom
Kardiologisk Forskningsenhed 2161, Rigshospitalet
RECRUITING

Copenhagen, 2100, Denmark
Tartu University Hospital,
RECRUITING

Tartu, 50406, Estonia
University of East Anglia
NOT_YET_RECRUITING

Norwich, NR4 7TJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.